- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at…
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced…
Toronto, Ontario--(Newsfile Corp. - September 13, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K9) ("Quantum BioPharma" or…
Before the start of the ESMO congress, MEDSIR has brought together scientists, researchers, pharmaceutical companies, and patient association representatives to…
SHANGHAI, Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company…
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…
Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK),…
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues…
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…